ストックスクリーナーアプリを入手
8.35
6.81%
-0.605
アフターアワーズ：
8.35
Eyepoint Pharmaceuticals Inc (EYPT) 最新ニュース
EYPT (EyePoint Pharmaceuticals) Enterprise Value : $396.54 Mil (As of Nov. 20, 2024) - GuruFocus.com
EyePoint Pharmaceuticals (FRA:PV3B) Enterprise Value : €374.46 Mil (As of Nov. 20, 2024) - GuruFocus.com
EyePoint Pharmaceuticals Inc (NASDAQ: EYPT)’s Stock Reduces -12.58%, Making It A Good Investment - Stocks Register
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - The Manila Times
EyePoint Pharmaceuticals Awards 23,600 Stock Options to New Employees at $9.17 | EYPT Stock News - StockTitan
EyePoint Pharmaceuticals (NASDAQ:EYPT) Stock Price Down 8.5%What's Next? - MarketBeat
EyePoint Pharmaceuticals : Announces $16.5 Million Monetization of ILUVIEN Royalty with SWK Holdings Corporation - Marketscreener.com
HC Wainwright Has Pessimistic View of EYPT FY2024 Earnings - MarketBeat
EyePoint Pharmaceuticals: Low Price And Good Data Create An Opportunity - Seeking Alpha
Wall Street Analysts See a 175.07% Upside in EyePoint Pharmaceuticals (EYPT): Can the Stock Really Move This High? - Yahoo Finance
EyePoint price target lowered to $33 from $38 at Baird - Yahoo Finance
(EYPT) Technical Data - Stock Traders Daily
EyePoint Pharmaceuticals Reports $29.4 Million Third Quarter Net Loss - Vision Monday
EyePoint shares retain Outperform as Baird sees upside in DME and wet AMD opportunities - Investing.com
EyePoint Pharmaceuticals, Inc.’s US$161 Million Public Offering Of Common Stock - Global Legal Chronicle
H.C. Wainwright trims EyePoint stock target, highlights cash runway extension to 2027 - Investing.com
EyePoint Pharmaceuticals (NASDAQ:EYPT) Price Target Cut to $22.00 by Analysts at HC Wainwright - MarketBeat
EyePoint Pharmaceuticals (NASDAQ:EYPT) Price Target Cut to $33.00 by Analysts at Robert W. Baird - MarketBeat
EyePoint Pharmaceuticals (NASDAQ:EYPT) Price Target Raised to $33.00 - MarketBeat
EyePoint Pharmaceuticals Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance Australia
EyePoint Pharmaceuticals Advances in Retinal Therapeutics - TipRanks
EyePoint Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
EyePoint Pharmaceuticals (EYPT) Reports Q3 Loss, Lags Revenue Estimates - Yahoo Finance
EyePoint Pharmaceuticals: Q3 Earnings Snapshot - San Francisco Chronicle
EyePoint Pharmaceuticals Reports Third Quarter 2024 Financial Results and Highlights Recent Corporate Developments - The Manila Times
Federated Hermes, Inc. Expands Stake in EyePoint Pharmaceuticals Inc - GuruFocus.com
Finance Watch: Syndax Raises $350m, KalVista Gets $100m In Royalty Deals - Scrip
With 61% ownership, EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) boasts of strong institutional backing - Yahoo Finance
Vanguard Group Inc's Strategic Acquisition in EyePoint Pharmaceu - GuruFocus.com
EyePoint Pharmaceuticals (NASDAQ:EYPT) Trading Down 5.4%What's Next? - MarketBeat
EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences - The Manila Times
EyePoint Pharmaceuticals Announces Successful Closure of Underwritten Public Offering WATERTOWN, Mass., October 31, 2024 – EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) recently finalized its underwritten public offering of 14,636,363 shares - Defense World
EYPTEyePoint Pharmaceuticals, Inc. Latest Stock News & Market Updates - StockTitan
When (EYPT) Moves Investors should Listen - Stock Traders Daily
EyePoint rises on interim data for mid-stage trial of its diabetic macular edema therapy - MSN
EyePoint Pharmaceuticals Announces Closing of Upsized Public Offering and Full Exercise of Option to Purchase Additional Shares - The Manila Times
EyePoint Pharmaceuticals prices $140M share offering - MSN
EyePoint Pharmaceuticals (NASDAQ:EYPT) Sees Strong Trading VolumeWhat's Next? - MarketBeat
EyePoint Pharmaceuticals (EYPT) Soars 27.6%: Is Further Upside Left in the Stock? - MSN
EyePoint Pharmaceuticals Announces Pricing of Upsized Public Offering - The Manila Times
Guggenheim maintains Buy on EyePoint with $68 target - Investing.com India
EyePoint Pharmaceuticals Announces Pricing of Upsized Public Offering - GlobeNewswire Inc.
EyePoint Pharmaceuticals (NASDAQ:EYPT) Trading Down 6.5%Should You Sell? - MarketBeat
EyePoint launches $100 million public stock offering By Investing.com - Investing.com Australia
EyePoint Pharmaceuticals (NASDAQ:EYPT) Stock Rating Reaffirmed by Chardan Capital - MarketBeat
Revenues Not Telling The Story For EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) After Shares Rise 52% - Simply Wall St
‘Really competitive’ tax breaks keep EyePoint manufacturing in Mass. - The Business Journals
PROCEPT BioRobotics Posts Strong Q3 Earnings, Joins Monte Rosa Therapeutics, EyePoint Pharmaceuticals And Other Big Stocks Moving Higher On Monday - MSN
Coinbase Global Inc Cl A (COIN-Q) QuotePress Release - The Globe and Mail
HC Wainwright Reaffirms Buy Rating for EyePoint Pharmaceuticals (NASDAQ:EYPT) - Defense World
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Receives Consensus Rating of "Buy" from Analysts - MarketBeat
EyePoint shares hold as analyst reiterates Buy rating By Investing.com - Investing.com South Africa
EyePoint reports positive DURAVYU trial results for DME By Investing.com - Investing.com South Africa
EyePoint launches $100 million public stock offering - Investing.com India
EyePoint Pharmaceuticals Announces Proposed Public Offering of Common Stock - The Manila Times
0.93%
3.56%
大文字化:
|
ボリューム (24 時間):